<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36999228</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Hopes and concerns regarding the implementation of expanded access protocols in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>433</StartPage><EndPage>435</EndPage><MedlinePgn>433-435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27828</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ikjae</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0537-9622</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-8574-5332</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Penn State College of Medicine, Hershey, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Muscle Nerve. 2023 Jun;67(6):456-463</RefSource><PMID Version="1">36929648</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EAP</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">compassionate use</Keyword><Keyword MajorTopicYN="N">expanded access</Keyword><Keyword MajorTopicYN="N">expanded access protocol</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>2</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36999228</ArticleId><ArticleId IdType="doi">10.1002/mus.27828</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole study group. N Engl J Med. 1994;330(9):585-591.</Citation></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512.</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium Phenylbutyrate-Taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919-930.</Citation></Reference><Reference><Citation>Yerton M, Winter A, Gelevski D, et al. Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS). Muscle Nerve. 2023;67(6):456-463. doi:10.1002/mus.27819.</Citation></Reference><Reference><Citation>FDA Releases Action Plan for Rare Neurodegenerative Diseases Including ALS, U.S. FOOD &amp; DRUG ADMINSTRATION website, https://www.fda.gov/news-events/press-announcements/fda-releases-action-plan-rare-neurodegenerative-diseases-including-als, updated June 23, 2022. Accessed March 28, 2023.</Citation></Reference><Reference><Citation>Expanded Access. U.S. FOOD &amp; DRUG ADMINISTRATION website, https://www.fda.gov/news-events/public-health-focus/expanded-access, updated December 21, 2022. Accessed March 28, 2023.</Citation></Reference><Reference><Citation>New Drug, Antibiotic, and Biologic Drug Product Regulations. U.S. FOOD &amp; DRUG ADMINISTRATION website, http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm120111.htm, updated September 22, 2015. Accessed March 28, 2023.</Citation></Reference><Reference><Citation>Jarow JP, Lurie P, Ikenberry SC, Lemery S. Overview of FDA's expanded access program for investigational drugs. Ther Innov Regul Sci. 2017;51(2):177-179.</Citation></Reference><Reference><Citation>Agarwal R, Saltz LB. Understanding the right to try act. Clin Cancer Res. 2020;26(2):340-343.</Citation></Reference><Reference><Citation>Right to Try. U.S. FOOD &amp; DRUG ADMINSTRATION website, https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try, updated January 23, 2023. Accessed March 28, 2023.</Citation></Reference><Reference><Citation>Walker S. Expanded access versus right-to-try. Hosp Pharm. 2020;55(2):79-81.</Citation></Reference><Reference><Citation>Expanded Access Submission Data. U.S. FOOD &amp; DRUG ADMINSTRATION website, https://www.fda.gov/news-events/expanded-access/expanded-access-compassionate-use-submission-data, updated November 03, 2022. Accessed March 28, 2023.</Citation></Reference><Reference><Citation>An Intermediate Size Expanded Access Protocol of AMX0035 for ALS. ClinicalTrialsgov website, https://clinicaltrials.gov/ct2/show/NCT05286372?term=sodium+phenylbutyrate&amp;cond=Amyotrophic+Lateral+Sclerosis&amp;draw=2&amp;rank=2, updated October 18, 2022. Accessed March 28, 2023</Citation></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31-39.</Citation></Reference><Reference><Citation>A path forward: strategic priorities for amyotrophic lateral sclerosis (ALS), NIH/National Institute of Neurological Disorders and Stroke website, https://www.ninds.nih.gov/news-events/directors-messages/all-directors-messages/path-forward-strategic-priorities-amyotrophic-lateral-sclerosis-als, updated February 2, 2023. Accessed March 28, 2023.</Citation></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20&#x2009;years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68.</Citation></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61(4):456-464.</Citation></Reference><Reference><Citation>Dupuis L, Dengler R, Heneka MT, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012;7(6):e37885.</Citation></Reference><Reference><Citation>Galin S, Heruti I, Barak N, Gotkine M. Hope and self-efficacy are associated with better satisfaction with life in people with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7-8):611-618.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>